Company: ARTL
Filing Date: 2025-10-01
Form Type: 8-K
Source: 0001640334-25-001766
Chunk: 0

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-10-01
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01 Entry into a Material Definitive Agreement.

On September 30, 2025, Artelo Biosciences, Inc. (the “ Company”) entered into an Underwriting Agreement (the “ Underwriting Agreement”) with R. F. Lafferty & Co., Inc., the sole book-running manager and underwriter (the “ Underwriter”), relating to an underwritten offering (the “ Offering”) of (i) 441,210 shares (the “ Shares”) of common stock, par value $0.001 per share, of the Company (the “ Common Stock”) at a price to the public of $4.40 per share (the “ Share Purchase Price”), and (ii) pre-funded warrants to purchase up to 13,335 shares of Common Stock at an exercise price of $0.001 per share (the “ Pre-funded Warrants” and together with the Shares, the “ Securities”) at a price to the public of $4.399 per Pre-funded Warrant (the “ Pre-funded Warrant Purchase Price”), for aggregate gross proceeds of approximately $2 million, before deducting underwriting discounts and commissions and the other estimated Offering expenses. Pursuant to the Underwriting Agreement, the Company has granted the Underwriter a 45-day option to purchase up to an additional 68,181 shares of Common Stock at the Share Purchase Price per share and/or Pre-funded Warrants at the Pre-funded Warrant Purchase Price, less the underwriting discounts to cover over-allotments, if any.

Each Pre-funded Warrant is exercisable for one share of our Common Stock, with an exercise price equal to $0.001 per share, is immediately exercisable and terminates once exercised in full. A holder of Pre-funded Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% (the “ Ownership Limitation”) of the number of shares of the Company’s Common Stock outstanding immediately after giving effect to such exercise. A holder of Pre-funded Warrants may increase or decrease the Ownership Limitation by providing at least 61 days’ prior notice to the Company.

The Offering was closed on October 1, 2025 (the “ Closing Date”). The Company delivered the Securities to the Underwriter on the same day.

The Company intends to use the net proceeds from the Offering to advance its product candidates through preclinical and clinical development, including manufacturing, research and technical development, clinical studies, capital expenditures, and for